https://www.selleckchem.com/products/az32.html
AOM/DSS induced significant bodyweight loss throughout the trial (max -36%), which was attenuated by Saireito (max +7%), EO (max +5%) and EO/Saireito (max +14%; p0.05). AOM/DSS increased DAI compared to saline controls (p0.05), which was reduced by Saireito, EO and EO/Saireito (p0.05). All treatments reduced colonoscopically-assessed colitis severity (days 20 and 41; p0.05). EO/Saireito further decreased colitis severity compared to Saireito and EO alone (day 20; p0.05). Finally, EO and EO/Saireito resulted in fewer col
Curtir
Comentario
Compartilhar
